Natera shows relative strength — will the breakout now succeed?

Meanwhile, we are seeing more and more tradeable setups again, with many stocks showing signs of a double bottom. This is also the case for one of the leading providers of cell-free DNA tests, Natera, which specializes in diagnostic tests for women's health, oncology, and organ transplantation. The company has introduced Signatera, a personalized test for circulating tumor DNA (ctDNA) that can detect molecular traces of residual cancer cells or minimal residual disease (MRD) in the patient's circulating blood. New data indicates that this test...